Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 1
2016 1
2017 2
2018 3
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Results by year
Filters applied: . Clear all
Page 1
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).
Forster M, Hackshaw A, De Pas T, Cobo M, Garrido P, Summers Y, Dingemans AC, Flynn M, Schnell D, von Wangenheim U, Loembé AB, Kaiser R, Lee SM. Forster M, et al. Among authors: loembe ab. Lung Cancer. 2018 Jun;120:27-33. doi: 10.1016/j.lungcan.2018.03.007. Epub 2018 Mar 9. Lung Cancer. 2018. PMID: 29748012 Free article. Clinical Trial.
Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.
Kim ST, Smith SA, Mortimer P, Loembé AB, Cho H, Kim KM, Smith C, Willis S, Irurzun-Arana I, Berges A, Hong JY, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kozarewa I, Pierce AJ, Dean E, Lee J. Kim ST, et al. Among authors: loembe ab. Clin Cancer Res. 2021 May 11. doi: 10.1158/1078-0432.CCR-21-0251. Online ahead of print. Clin Cancer Res. 2021. PMID: 33975862 Free article.
A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma.
Palmer DH, Ma YT, Peck-Radosavljevic M, Ross P, Graham J, Fartoux L, Deptala A, Studeny M, Schnell D, Hocke J, Loembé AB, Meyer T. Palmer DH, et al. Among authors: loembe ab. Br J Cancer. 2018 May;118(9):1162-1168. doi: 10.1038/s41416-018-0051-8. Epub 2018 Mar 22. Br J Cancer. 2018. PMID: 29563636 Free PMC article. Clinical Trial.
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, John T, Leighl NB, Reck M, Taylor P, Planchard D, Sørensen JB, Socinski MA, von Wangenheim U, Loembé AB, Barrueco J, Morsli N, Scagliotti G. Grosso F, et al. Among authors: loembe ab. J Clin Oncol. 2017 Nov 1;35(31):3591-3600. doi: 10.1200/JCO.2017.72.9012. Epub 2017 Sep 11. J Clin Oncol. 2017. PMID: 28892431 Free article. Clinical Trial.
Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study.
Eisen T, Shparyk Y, Macleod N, Jones R, Wallenstein G, Temple G, Khder Y, Dallinger C, Studeny M, Loembe AB, Bondarenko I. Eisen T, et al. Among authors: loembe ab. Invest New Drugs. 2013 Oct;31(5):1283-93. doi: 10.1007/s10637-013-9962-7. Epub 2013 Apr 27. Invest New Drugs. 2013. PMID: 23625328 Clinical Trial.